Physician profile
Edwin A Wymer
NPI 1912975996
$721.13
in general payments reported to CMS, 2019-2025
12 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.53 · 2020: $60.22 · 2021: $63.80 · 2022: $112 · 2023: $137 · 2024: $135 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.95 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $113.82 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $113.37 | 2025 | Neffy |
| Pfizer INC. | $87.01 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $72.14 | 2020-2023 | Varivax, Vaxneuvance, Gardasil 9 |
| Cranial Technologies, INC | $63.86 | 2019-2025 | Doc Band |
| Aytu Biopharma, INC. | $30.07 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $28.57 | 2019-2020 | |
| Neurelis, INC. | $15.99 | 2024 | Valtoco |
| Biomarin Pharmaceutical INC. | $14.86 | 2024 | |
| Sobi, INC | $13.47 | 2023 | |
| Kaleo, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Wymer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.